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Chemotherapeutic drugs are widely used for the treatment of cancer; however, use of these drugs is often associated with
patient toxicity and poor tumor delivery. Micellar drug carriers oﬀer a promising approach for formulating and achieving
improved delivery of hydrophobic chemotherapeutic drugs; however, conventional micelles do not have long-term stability in
complex biological environments such as plasma. To address this problem, a novel triblock copolymer has been developed to
encapsulate several diﬀerent hydrophobic drugs into stable polymer micelles. These micelles have been engineered to be stable
at low concentrations even in complex biological ﬂuids, and to release cargo in response to low pH environments, such as in
the tumor microenvironment or in tumor cell endosomes. The particle sizes of drugs encapsulated ranged between 30–80nm,
with no relationship to the hydrophobicity of the drug. Stabilization of the micelles below the critical micelle concentration was
demonstrated using a pH-reversible crosslinking mechanism, with proof-of-concept demonstrated in both in vitro and in vivo
models. Described herein is polymer micelle drug delivery system that enables encapsulation and stabilization of a wide variety of
chemotherapeutic drugs in a single platform.
1.Introduction
It was estimated that there were 1,500,000 new cancer cases
and approximately 560,000 deaths from cancer in 2010 [1].
The use of chemotherapy has dramatically improved the sur-
vival rate of patients for the last several decades; however,
stand-alone chemotherapy drugs suﬀer from numerous
problems including rapid in vivo metabolism and/or excre-
tion, inability to access and penetrate cancer cells, and non-
speciﬁc uptake by healthy cells and tissue. Often, a large per-
centage of cytotoxic drug administered to the patient does
not reach the tumor environment but rather is distributed
throughoutthebody,resultinginthemanytoxiceﬀectsasso-
ciated with chemotherapy and a narrowing of the drug’s
therapeutic window. Polymer micelles oﬀer a promising
approachtoachievingthesegoalsduetotheirinherentability
to overcome multiple biological barriers, such as avoidance
of the reticuloendothelial system (RES) [2]. Due to their
unique size range (20–150nm), micelles are able to avoid
renal clearance (typically less than 20nm) and uptake by
the liver and spleen (particles greater than 150nm). These
micelles can also preferentially accumulate in solid tumors
via the enhanced permeation and retention (EPR) eﬀect
[3, 4]. The EPR eﬀect is a consequence of the disorganized
nature of the tumor vasculature, which results in increased
permeability of polymer therapeutics and drug retention at
the tumor site.
When considering the design of a nanocarrier, several
important factors should be addressed. An ideal delivery sys-
tem should be composed of biocompatible and biodegrad-
able materials, reproducibly assemble into the desired size
range, encapsulate a wide range of drugs and drug classes,2 Journal of Drug Delivery
maintain particle size in biological media, have the ability
to attach cell-speciﬁc targeting groups, and release the ther-
apeutic at the site of disease. Polymer micelles have received
much attention over the past thirty years as drug delivery
vehicle [5–11]. In traditional micelle systems, however, there
are no mechanisms in place to keep the micelle intact when
it is diluted in the bloodstream, where it is below the crit-
ical micelle concentration and interacts with surfactant pro-
teins within the blood. Thus, stability of nano-carriers in
biological media remains an issue that needs to be addressed
[12]. Some have utilized the approach of chemically conju-
gating the active drug to a polymer to potentially improve
stability. However, this “prodrug” approach is dependent
on enzymatic or chemical cleavage of the bond to release
the active drug [13–15]. In an attempt to add stability to
the micelle, various types of micelles have been developed
whereby either the core or shell of the micelle has incorpo-
rated crosslinking chemistries, thereby imparting stability at
low micelle concentrations [16–22]. However, in many cases,
crosslinkingisachievedutilizingcovalentbondingwithinthe
micelle, which does not lend itself to tunable drug release.
In addition, in some crosslinked micelles, the crosslinks are
physically located with the drug in the core of the micelle,
whichmayinterferewithpharmaceuticaldrugactionordrug
release from the micelle.
This paper describes a polymer micelle drug delivery
system (IVECT) that has eﬀectively addressed the limitations
of traditional polymer micelles, by forming micelles that
are stable in biological environments. The IVECT triblock
copolymer consists of poly(ethylene glycol)-b-poly(aspartic
acid)-b-poly(D-leucine-co-tyrosine). The leucine/tyrosine
core unit in this polymer is able to encapsulate a wide variety
of hydrophobic molecules, which is enhanced by the use of
both D and L stereoisomers. The poly(aspartic acid) block
was designed to participate in a metal-acetate crosslinking
reaction that eﬀectively stabilized drugs inside the core of
the micelle and also mediates pH-dependent release of the
drug. In this paper, a polymer micelle is described that is
composed of biocompatible materials, has the versatility to
encapsulate a wide range of therapeutic payloads, is stable to
dilution within the blood stream, and has a tunable, highly
sensitive, and reversible stabilization mechanism. Data are
presented whereby several diﬀerent hydrophobic molecules
are encapsulated and stabilized by crosslinking using a single
polymer and without physical manipulation of the drug.
2.MaterialsandMethods
2.1. Chemicals and Reagents. All chemicals were obtained
from Aldrich or Fisher unless otherwise speciﬁed. N3-
PEG12k-NH-BOC was prepared as described previously
[23]. N-carboxy anhydrides (NCAs) were prepared accord-
ing to previously published procedures. [24, 25]. N-methyl-
pyrrolidone (NMP) was distilled prior to use. BB4007431
and NX-8 were provided by Novartis. Daunorubicin and
doxorubicin were obtained from LGM Pharma (Boca Raton,
FL). All other drugs were obtained from Yingxuan Pharma-
ceuticals (Shanghai, China).
2.2. Synthesis of Triblock Copolymer. N3-PEG12K-NH-Boc
(150g, 12.5mmol) was dissolved into 1L of CH2Cl2/DFA
(70/30) and was allowed to stir at room temperature over-
night. The product was precipitated twice in diethyl ether
andwasrecoveredasawhitepowder(yield ∼90%). 1HNMR
(d6-DMSO) 7.77 (3H), 5.97 (1H), 3.83–3.21 (1050H), 2.98
(2H) ppm.
N3-PEG12K-NH3/DFA (95g, 7.92mmol) was weighed
into an oven-dried, 2L-round-bottom ﬂask and was left
under vacuum for three hours before adding the NCA.
Asp(OBu) NCA (17.04g, 79.2mmol) was added to the ﬂask,
and the ﬂask was evacuated under reduced pressure and sub-
sequently backﬁlled with nitrogen gas. Dry NMP (560mL)
was introduced by cannula, and the solution was heated to
60◦C. The reaction mixture was allowed to stir for 24 hours
at 60◦C under nitrogen gas. Then, D-Leu NCA (24.88g,
158mmol) and Tyr (OBzl) NCA (47.08g, 158mmol) were
dissolved under nitrogen gas into 360mL of NMP into an
oven-dried, round-bottom ﬂask, and the mixture was subse-
quently added to the polymerization reaction via a syringe.
The solution was allowed to stir at 60◦C for another three
days at which point the reaction was complete (as deter-
mined by HPLC). The solution was cooled to room tempera-
ture, and diisopropylethylamine (DIPEA) (10mL), dimethy-
laminopyridine (DMAP) (100mg), and acetic anhydride
(10mL) were added. Stirring was continued for 1 hour at
room temperature. The polymer was precipitated into dieth-
yl ether (10L) and isolated by ﬁltration. The solid was redis-
solved in dichloromethane (500mL) and precipitated into
diethyl ether (10L). The product was isolated by ﬁltration
and dried in vacuo to give the block copolymer as an oﬀ-
white powder (134.6g, yield = 73%). 1HN M R( d 6-DMSO)
δ 8.43–7.62 (50H), 7.35 (100H), 7.1 (40H), 6.82 (40H),
4.96 (40H), 4.63–3.99 (50H), 3.74–3.2 (1500H), 3.06–2.6
(60H), 1.36 (90H), 1.27–0.47 (180).
N3-PEG12K-b-poly(Asp(OBu)10)-b-poly(Tyr(OBzl)20-
co-D-Leu20)-Ac (134.6g, 6.4mmol) was dissolved into 1L of
a solution of pentamethylbenzene (PMB, 0.5M) in triﬂuoro-
acetic acid (TFA). The reaction was allowed to stir for ﬁve
hours at room temperature. The solution was precipitated
into a 10-fold excess of diethyl ether, and the solid was recov-
ered by ﬁltration. The polymer was redissolved into 800mL
of dichloromethane and precipitated into diethyl ether. An
oﬀ-white polymer was obtained after drying the product
overnight in vacuo (111.8g, yield = 93%). 1H NMR (d6-
DMSO) δ 12.2 (10H), 9.1 (10H), 8.51–7.71 (50H), 6.96
(40H), 6.59 (40H), 4.69–3.96 (60H), 3.81–3.25 (1500H),
3.06–2.65 (60H), 1.0–0.43 (180). 1H NMR (d6-DMSO) δ
171.9, 171, 170.5, 170.3, 155.9, 130.6, 129.6, 127.9, 115.3,
114.3, 70.7, 69.8, 54.5, 51.5, 50, 49.8, 49.4, 36.9, 36, 24.3,
23.3, 22.3, 21.2. IR (ATR) 3290, 2882, 1733, 1658, 1342,
1102, 962cm−1. The ﬁnal composition of the polymer
is N3-PEG12K-b-poly(Asp)10-b-poly(Tyr20-co-D-Leu20)-Ac,
which is also referred to as poly(ethylene glycol)-b-poly
(aspartic acid)-b-poly(D-leucine-co-tyrosine).
2.3. Micelle Production. All formulations were prepared
using oil-in-water emulsion techniques involving dissolvingJournal of Drug Delivery 3
the polymer in water and the drug in an organic solvent. An
exemplary formulation technique for daunorubicin follows.
The IVECT triblock copolymer (3g) was dissolved in wa-ter
(500mL). Daunorubicin (301mg) was dissolved in dichlo-
romethane (48mL) and methanol (12mL). Just prior to use,
triethylamine (0.28mL) was added to the organic solution to
complete the dissolution of the daunorubicin. The aqueous
solution was mixed with a Silverson LRT-4 shear mixer (ﬁne
emulsor screen, 10,000RPM). Daunorubicin was added to
the mixed solution in a single portion over ∼10s. The solu-
tion was mixed for an additional minute and then stirred at
roomtemperatureovernight.Theresultingsolutionwasthen
ﬁltered through a 0.22μm PES ﬁlter (Millipore Stericup).
Iron (II) chloride solution was added to the concentrated
micelle solution at a concentration of 10mM, and the pH
was adjusted to 8.0 and stirred overnight. This solution was
frozen on a shell freezer at −40◦C and then lyophilized on a
Labconco 6L Plus manifold lyophilization system operating
at a pressure of 0.050Torr and a collector temperature
of −85◦C. After 48h, crosslinked, daunorubicin-loaded
micelles were recovered as a purple powder (3.22g, 93%
yield).
2.4. Drug Weight Loading by HPLC. The mass percentage of
activedrugwithintheformulationwasdeterminedbyHPLC.
An exemplary procedure for daunorubicin follows. The dau-
norubicin-loaded micelle was analyzed by a Waters Alliance
separations module (W2695) equipped with Waters Nova-
pak C18, 4μm column (no. WAT086344) coupled with a
Waters Photodiode Array Detector (W2998). Daunorubicin
was detected at an absorbance of 480nm. Mobile phase
consisted of a 10:70:20 ratio of methanol:10mM phos-
phate buﬀer pH 2.0:acetonitrile over a 10-minute gradi-
ent. Known standards of free daunorubicin were used to
determine the percentage by weight of daunorubicin in the
formulation (wt/wt%).
2.5. Particle Size Analysis. Particle sizes were determined us-
ing dynamic light scattering on a Wyatt DynaPro (Santa Bar-
bara, CA). Following lyophilization, micelles were dissolved
at 1mg/mL in 150mM NaCl and were centrifuged at 2,000
RPM prior to analysis to remove dust.
2.6. Encapsulation, Crosslinking, and pH-Dependent Release
Dialysis. To test drug encapsulation, the uncrosslinked for-
mulation was dissolved at a concentration of 20mg/mL in
water, which is above the critical micelle concentration of
the polymer. Two milliliters were dialyzed in a 3500MWCO
dialysis bag in a volume of 300mL of 10mM phosphate buﬀ-
er, pH 8.0. After dialysis for six hours, the pre- and post-
dialysis samples from inside the bag were quantiﬁed for drug
concentration by HPLC. Encapsulation retention was calcu-
lated by dividing the postdrug concentration by the precon-
centration.
To test crosslinking, the crosslinked formulation was
dissolved in water at a concentration of 0.2mg/mL, which is
below the critical micelle concentration. Three milliliters
were dialyzed in a 3500MWCO dialysis bag in a volume
of 300mL of 10mM phosphate buﬀer pH 8. After dialysis
for six hours, the pre- and postdialysis samples from inside
the bag were quantiﬁed for drug concentration by HPLC.
Crosslinking retention was calculated by dividing the post-
drug concentration by the preconcentration. For pH-de-
pendent release, samples were treated the same as for cross-
linking dialysisexceptfordialysisin10mMphosphatebuﬀer
pH 3, 4, 5, 6, 7, 7.4, or 8.
2.7. In Vivo Pharmacokinetic Studies. Female Sprague-Daw-
leyratsweighingabout220gwithjugularveincatheterswere
obtained from Harlan. Rats were randomly divided into
groups of four and were given a single injection of free drug,
uncrosslinked drug loaded micelles, or crosslinked, drug
loaded micelles dissolved in 150mM NaCl. Daunorubicin
micelles were injected at 10mg/kg daunorubicin-equivalent
dosing, and BB4007431 micelles were injected through the
catheter at 25mg/kg BB4007431 drug-equivalent dosing.
Free BB4007431 was dissolved in 0.33M lactic acid/1.67%
dextrose and then diluted in 5% dextrose in water for
injection. About 0.25mL of blood was collected through the
catheter at 1, 5, 15min, 1h, 4h, 8h, and 24h. Samples were
centrifuged at 2000RPM for 5 minutes to separate plasma.
Plasma was then diluted 1:4 in cold 0.1% phosphoric acid
in methanol with an appropriate internal standard, vortexed
for 10 minutes, and centrifuged for 13,000RPM for 10
minutes. The supernatant was then analyzed by HPLC to
determine the drug concentration for each sample. Plasma
concentrations were plotted in Microsoft Excel to determine
AUC values. Animals were maintained in accordance with
The Public Health Service Policy on Humane Care and Use
of Laboratory Animals, and the Institutional Animal Care and
UseCommittee’s(IACUC)PrinciplesandProceduresofAnimal
Care and Use.
3. Results
The IVECT triblock copolymer consists of poly(ethylene
glycol)-b-poly(aspartic acid)-b-poly(D-leucine-co-tyrosine),
in which each segment is biodegradable or biocompatible
and plays a very important role (Figure 1). Hydrophobic
drugs that are loaded into the micelle reside in the encap-
sulation block (yellow), forming the core of the micelle. The
poly(aspartic acid) middle block (green) is the crosslinking
block that stabilizes the micelle. In contrast to crosslinking in
the core or periphery of the micelle, Intezyne has developed
pH-reversible crosslinking technology in the middle block
of the triblock copolymer. Crosslinking of this middle layer
of the micelle is advantageous since it does not interfere
with the core region, which is where the drug resides. The
chemistry utilized to crosslink the polymer chains together,
and thus stabilizes the micelle, is based on metal acetate
chemistry (Figure 2).Itis wellknown thatanumber ofmetal
ions can interact with carboxylic acids to form metal-acetate
bonds [26]. It is also understood that these ligation events
form rapidly when the carboxylic acid is in the carboxylate
form (e.g., high pH, pH ∼ 7-8) yet only weakly interact
when the carboxylic acids are fully protonated (e.g., low4 Journal of Drug Delivery
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Figure 1: The IVECT polymer micelle. Drugs are loaded into the core hydrophobic block (yellow). The crosslinking block (green) provides
stability to the micelle by forming pH-reversible metal-acetate bonds that allow for triggered drug release near the tumor. The PEG block
(gray) gives the micelle aqueous solubility and stealth properties in vivo.
pH, pH 4-5), therefore allowing release of the drug in low-
pH environments, such as regions surrounding the tumor,
and the endosomes of tumor cells following endocytosis of
micelles. The poly(ethylene glycol) block (Figure 1, shown
in gray) allows for water solubility and provides “stealth”
properties to the micelle in order to avoid protein opsoniza-
tion and the reticuloendothelial system [2].
As an initial study, the triblock copolymer was used to
encapsulate several diﬀerent small molecule drugs with vary-
ing hydrophobicities. A trend was discovered such that the
abilityofthetriblocktoencapsulateadrugwasdependenton
the drug’s LogP value. Eﬀective encapsulation was achieved
with molecules having a Log P>1.4( Figure 3). The
weight loadings of the formulations ranged between 1 and
20%. Molecules that were encapsulated were subsequently
crosslinked by the addition of iron chloride. The addition
of iron chloride to the micelle did not aﬀect the drug and
did not result in generation of polymer-drug conjugates. To
test stability of the crosslinked micelle, the in vitro stability of
the micelle below the CMC was determined using a dialysis
assay. In contrast to the encapsulation retention, there was
noclearcorrelationbetweentheLogP valueandcrosslinking
retention (Table 1). The particle sizes of crosslinked micelles,
as determined by dynamic light scattering, also did not seem
related to the LogP value. These results demonstrate that the
hydrophobicity of the drug inﬂuences its ability to be en-
capsulated within the micelle, but does not inﬂuence cross-
linking retention or particle size.
Todeterminewhethercrosslinkedmicellesexhibited pH-
dependent release, diﬀerent micelles were dialyzed at con-
centrations below the CMC in 10mM phosphate buﬀer of
diﬀerent pHs. Crosslinked micelles containing BB4007431
Table 1: Drug formulation properties. The encapsulation retention
percentage, crosslinking retention percentage, and particle sizes are
shown for eleven compounds tested for loading within the polymer
micelle.
Drug LogP Encapsulation
retention (%)
Crosslinking
retention (%)
Particle size
(nm)
5-Fluorouracil −0.58 0 NA ND
Caﬀeine −0.24 0 NA ND
Melphalan −0.22 0 NA ND
Gemcitabine 0.14 0 NA ND
Etoposide 0.73 12 NA ND
Doxorubicin 1.41 80 63 30
Daunorubicin 1.68 85 78 30
BB4007431 1.94 79 90 55
Paclitaxel 3.2 93 60 36
NX-8 4.18 86 52 86
Vinorelbine 4.39 87 37 47
NA: not applicable, ND: not determined.
demonstrated pH-dependent release of the drug, with in-
creased retention of the drug within the micelle at pH 8,
and near total release of the drug after incubation at pH 3
(Figure 4(a)). In contrast, uncrosslinked micelles containing
BB4007431 showed nearly complete release of the drug at all
pHs, reﬂecting the instability of the uncrosslinked micelle.
To assess the eﬀect of salt in the stability of the micelle,
crosslinked BB4007431 was diluted below the CMC and
dialyzed in 10mM phosphate buﬀer or phosphate-buﬀered
saline (PBS) at diﬀerent pHs (Figure 4(b)). This experimentJournal of Drug Delivery 5
O
O O O
O
Fe
Fe
Fe
Fe
O
O
N N
H
O
N
H
H
N
H
O
OH O
O
OH
OH R
O
O
O O O O
O
N N
H
O
N
H
H
N
H
O
OH O
OH
O
O O O O
O
N N
H
O
N
H
H
N
H
O
O O
O O
Fe
Fe
MX2   +   2
R R M
O
O
O
O
+   2HX
−HX
+HX
Figure 2: Metal-acetate crosslinking chemistry for stabilization of polymer micelles. While the drug is localized in the core block, the
poly(asparticacid)blockofthemiddleblockreactswithmetalstoformmetalacetatebonds.BondsareformedathighpHandaredissociated
at low pH. M represents metal, and X represents a halogen.
showed that salt did destabilize the crosslinked micelle to
some degree, but a pH-dependent release was still exhibited.
In order to test the stability of the micelle in vivo,a
crosslinked, daunorubicin-loaded micelle was assessed in a
pharmacokinetic study. Rats were intravenously injected
with10mg/kg offree daunorubicin, uncrosslinked daunoru-
bicin micelle, or crosslinked daunorubicin micelle, and the
concentration of daunorubicin in plasma was determined
overthecourseoftwentyfourhours(Figure 5).Resultsdem-
onstrated that the crosslinked daunorubicin micelle exhib-
ited 90-fold increase in plasma in AUC compared to free
daunorubicin and 78-fold increase in AUC compared to un-
crosslinkeddaunorubicin.Crosslinkeddaunorubicinalsoex-
hibited a 46-fold higher Cmax t h a nf r e ed a u n o r u b i c i na n da
59-fold increase compared to uncrosslinked micelle. These
data demonstrate signiﬁcantly higher in vivo micelle stability
with the crosslinked daunorubicin micelle compared to the
free drug. A similar study was repeated with a crosslinked
formulation of compound BB4007431. Rats injected with
crosslinked BB4007431 micelle displayed a vastly superior
increase in Cmax (20-fold) and AUC (202.4-fold) compared
to free drug (Figure 6). Similar increases in stability were also
obtained with crosslinked doxorubicin and paclitaxel-loaded
micelles (data not shown), demonstrating the wide appli-
cability of this crosslinking technology to provide increased
drug stability in vivo.
4. Discussion
Improving stability of therapeutic molecules is a well-estab-
lished aim in the ﬁeld of drug delivery. An ideal drug-loaded
nanoparticle would be stable to dilution in biological media,
possess stealth-like properties to avoid uptake by the RES,
and release the drug only in the area of diseased tissue. The
data presented in this paper describe a versatile polymer
micelle drug delivery system that has been engineered to
eﬃciently encapsulate a wide variety of hydrophobic drugs.
In addition, the stabilization technology built-in to the mi-
celle is dependent on pH, such that the micelle is stable at
physiological pH, and unstable at low pH, thus providing a
mechanism to release the drug in the tumor microenviron-
ment or in endosomes, which are both slightly acidic envi-
ronments.
A vast number of drugs exist today that possess potent
anticancer activity; however, many of them are unable to be
utilized in the clinic due to their inability to be dissolved6 Journal of Drug Delivery
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Figure 3: Encapsulation retention of drugs within the micelle is
correlated to LogP value. The encapsulation retention of the drug,
based on an in vitro dialysis assay, is plotted compared to its LogP
value.
in aqueous solutions [27]. Some hydrophobic drugs can be
solubilized with excipients; however, such vehicles have been
shown to cause toxicity to the patient [28] .T h ec o r eb l o c k
of the triblock copolymer (poly(D-leucine-co-tyrosine)) was
rationally designed and chosen to encapsulate hydrophobic
molecules. A key factor leading to the versatility arises from
the use of both D and L stereoisomers of amino acids in
the core block, which disrupts the secondary structure of
the polypeptide. Replacing the rod-like helical nature of the
polypeptide with the ﬂexibility of a random coil allows for
signiﬁcant increases in drug loading eﬃciency. The ability of
drugs to be encapsulated within the triblock copolymer was
related to its LogP value, such that only hydrophobic drugs
could be encapsulated. This result is logical as hydrophilic
molecules would prefer to associate with the hydrophilic
part of the polymer versus the hydrophobic core, leading to
ineﬃcient drug encapsulation.
Crosslinking was performed using metal acetate chem-
istry, speciﬁcally, iron (II) chloride. The crosslinking dialysis
assay determined that 40–90% of the drug remained in the
crosslinkedmicelleaftersixhours.Typically,10%ofthedrug
orlesswasretainedinuncrosslinkedmicellesexaminedusing
the same crosslinking dialysis assay. Although there was a
correlation between LogP and encapsulation ability, there
was no clear correlation between LogP and the crosslinking
retention or the particle size. Therefore, it is hypothesized
that while hydrophobicity is a strong predictor of success for
encapsulation, other variables such as chemical functionality
and drug crystallinity play a signiﬁcant role in micelle size
and crosslinking eﬃciency.
While stability is important, equally important is the
ability to release the drug in a controlled fashion at the site of
disease. In vitro release assays demonstrated progressive re-
leaseofdrugfromthecoreofthemicelleasthepHdecreased,
which has physiological relevance for delivering drugs to
tumors. While passive targeting of nanoparticles within
tumor tissue is accomplished by the EPR eﬀect, an additional
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Figure 4: pH-dependent release of drug-loaded micelles. (a) Cross-
linked and uncrosslinked BB4007431 micelles were diluted below
the CMC and dialyzed for 6 hours in 10mM phosphate buﬀer at
diﬀerent pHs. The amount of drug retained before and after dialysis
was quantiﬁed by HPLC. (b) Crosslinked BB4007431 micelles were
diluted below the CMC and dialyzed for 6 hours in either 10mM
phosphate buﬀe r ,o rP B S ,a td i ﬀerent pHs. Drug content remaining
was quantiﬁed by HPLC as above.
layer of targeting is possible by employing active targeting
strategies, such as decorating the surface of nanoparticles
with targeting ligands [29–33]. It is logical to conclude, how-
ever, that the ability to target a nanoparticle to tumors is
dependent on the stability of the nanoparticle in vivo.I n
pharmacokinetic experiments, superior AUC and Cmax were
obtained with several crosslinked micelles, including dau-
norubicin and BB4007431, compared to their free drug or
uncrosslinked micelle counterparts. These data suggest thatJournal of Drug Delivery 7
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Figure 5: Pharmacokinetics of daunorubicin-loaded micelles in
rats. Sprague-Dawley rats were given a single intravenous admin-
istration of crosslinked daunorubicin micelle, uncrosslinked dau-
norubicin micelle, or free daunorubicin at a 10mg/kg dose. Plasma
wasanalyzedfordaunorubicinconcentrationatvarioustimepoints.
The table depicts the area under curve (AUC) and Cmax values for
each test article.
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Figure 6: Pharmacokinetics of crosslinked BB4007431 micelles in
rats. Sprague-Dawley rats were given a single intravenous admin-
istration of crosslinked BB4007431 micelle, or free BB4007431 at a
25mg/kg dose. Plasma was analyzed for BB4007431 concentration
atvarioustimepoints.Thetabledepictstheareaundercurve(AUC)
and Cmax values for each test article.
higher tumor accumulation, and correspondingly improved
antitumor eﬃcacy, would be achieved following administra-
tion of crosslinked micelle compared to free drug in mouse
biodistribution experiments. This would primarily be due to
passive targeting by the EPR eﬀect although active targeting
has the potential to even further improve delivery of cross-
linked micelles.
Polymer micelles hold great promise as drug delivery
agents.Indeed,manypolymermicellescarryingchemothera-
peutic drugs are currently in clinical trials [6, 34]. The utility
of a single platform to encapsulate and systemically deliver
hydrophobic cancer drugs allows for faster drug screening
and facilitated manufacturing processes. In addition to im-
provingthedeliveryofcurrentanticancerdrugs,thepolymer
micelle system presented herein holds promise for the devel-
opment of potent, but insoluble novel anticancer drugs. It is
envisioned that this new technology will ultimately provide
superior treatment options for patients with cancer.
5. Conclusions
A polymer micelle drug delivery system was developed that
demonstrated encapsulation and stabilization of a wide vari-
ety of hydrophobic anticancer drugs. Drug release from sta-
bilized micelles was determined to be pH dependent in vitro.
In vivo pharmacokinetic studies validated increased stability
ofcrosslinkedmicellesinbiologicalmediaanddemonstrated
improvedAUCandCmax comparedtouncrosslinkedmicelles
or free drug. These data demonstrate the utility and versa-
tility of a single platform to enable delivery of hydrophobic
anticancer drugs to solid tumors.
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